Literature DB >> 24581591

Non-cirrhotic portal hypertension--concept, diagnosis and clinical management.

Edna Strauss1, Dominique Valla2.   

Abstract

Non-cirrhotic portal hypertension (NCPH) is mainly related to vascular disorders in the portal system, granuloma formation with periportal fibrosis or genetic alterations affecting the hepatobiliary system. For the diagnosis of the so-called idiopathic NCPH, it is essential to rule out chronic liver diseases associated with progression to cirrhosis as viral hepatitis B and C, alcoholic and non-alcoholic fatty liver, autoimmune disease, hereditary hemochromatosis, Wilson's disease as well as primary biliary cirrhosis and primary sclerosing cholagitis. This mini review will focus on the most common types of NCPH, excluding the idiopathic NCPH. Primary Budd-Chiari syndrome, characterized by obstruction of hepatic venous outflow, must be distinguished from sinusoidal obstruction syndrome, a cause of portal hypertension associated with exposure to toxic plants or therapeutic agents. Noninvasive imaging methods usually help the diagnosis of both Budd-Chiari syndrome and portal thrombosis, the later a relatively frequent cause NCPH. Clinical presentation and management of these vascular disorders are evaluated. Schistosomiasis, a worldwide spread endemic parasitic disease, may evolve to severe forms of the disease with huge spleen and gastroesophageal varices due to presinusoidal portal hypertension. Although management of acute upper gastrointestinal bleeding is similar to that of cirrhosis, prevention of rebleeding differs. Instead of portosystemic shunt procedures, the esophagogastric devascularization with splenectomy is the accepted surgical alternative. Its association with endoscopic therapy is suggested to be the best option for PH due to schistosomiasis. In conclusion, the prompt diagnosis of the disorder leading to non-cirrhotic portal hypertension is essential for its correct management.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24581591     DOI: 10.1016/j.clinre.2013.12.012

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  6 in total

Review 1.  Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Authors:  Gyorgy Baffy
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

2.  Correlation of pressure gradient in three hepatic veins with portal pressure gradient.

Authors:  Hao-Yu Wang; Qing-Kun Song; Zhen-Dong Yue; Lei Wang; Zhen-Hua Fan; Yi-Fan Wu; Cheng-Bin Dong; Yu Zhang; Ming-Ming Meng; Ke Zhang; Li Jiang; Hui-Guo Ding; Yue-Ning Zhang; Yong-Ping Yang; Fu-Quan Liu
Journal:  World J Clin Cases       Date:  2022-05-16       Impact factor: 1.534

3.  Understanding the Pathophysiology of Portosystemic Shunt by Simulation Using an Electric Circuit.

Authors:  Moonhwan Kim; Keon-Young Lee
Journal:  Biomed Res Int       Date:  2016-10-27       Impact factor: 3.411

4.  Pulmonary shunts in severe hepatosplenic schistosomiasis: Diagnosis by contrast echocardiography and their relationship with abdominal ultrasound findings.

Authors:  Liana Gonçalves-Macedo; Ana Lucia Coutinho Domingues; Edmundo Pessoa Lopes; Carlos Feitosa Luna; Vitor Gomes Mota; Mônica Moraes de Chaves Becker; Brivaldo Markman-Filho
Journal:  PLoS Negl Trop Dis       Date:  2017-04-03

5.  Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Schistosomiasis-Induced Liver Fibrosis.

Authors:  Jiacheng Liu; Binqian Zhou; Dongpin Chen; Chen Zhou; Qin Shi; Chuansheng Zheng; Gansheng Feng; Feng Yuan; Yan Ge; Bin Xiong
Journal:  Cardiovasc Intervent Radiol       Date:  2019-07-30       Impact factor: 2.740

6.  Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension.

Authors:  Nikolaj Worm Ørntoft; Michel Blé; Anna Baiges; Jose Ferrusquia; Virginia Hernández-Gea; Fanny Turon; Marta Magaz; Søren Møller; Holger Jon Møller; Juan Carlos Garcia-Pagan; Henning Gronbaek
Journal:  Front Physiol       Date:  2021-06-11       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.